文献速递前列腺增生与排尿功能障碍

21世纪澳大利亚良性前列腺增生管理的趋势:基于人群数据的医疗与手术治疗变迁

Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data.
PubMed 文献 · BJU Int · 2020-06-17

该研究利用澳大利亚医保与药品福利计划2000–2018年人群数据分析良性前列腺增生(BPH)治疗趋势。结果显示BPH相关住院总数下降,但手术总率上升,TURP使用减少,激光与微创手术增加;药物治疗中度他雄胺/坦索罗辛联合及度他雄胺单药处方率显著上升,药物治疗费用负担急剧增加。

要点

  • BPH相关住院总数下降,但私立手术占比从42%升至77%。
  • TURP仍是最常用术式,但2009年后使用率从118降至89/10万男性。
  • 度他雄胺/坦索罗辛联合处方从111升至7649/10万男性。

核心结论

  • 尽管全国BPH相关住院减少,但药物治疗和TURP替代手术使BPH总体治疗增加。
  • BPH手术费用负担自2009年保持稳定,而药物治疗费用负担急剧上升。

研究设计与样本

  • 基于澳大利亚Medicare Benefits Schedule、Pharmaceutical Benefits Scheme及Australian Institute of Health and Welfare数据库2000–2018年年度数据的趋势分析。
  • 计算年龄调整的BPH手术与药物治疗率,并进行费用分析。

主要发现

  • BPH相关住院总数在2000–2018年间下降,私立手术占比从42%升至77%。
  • 度他雄胺/坦索罗辛联合治疗处方率从111升至7649/10万男性,度他雄胺单药从149升至336/10万男性。
  • BPH总手术率从92升至133/10万男性。
  • TURP使用率自2009年从118降至89/10万男性,被光选择性前列腺汽化、钬激光前列腺剜除及微创手术(前列腺尿道提升、Rezūm™等消融技术)替代。

关键数值与推荐

  • 2000–2018年BPH相关住院总数下降,私立手术占比42% vs 77%。
  • 度他雄胺/坦索罗辛联合处方率111 vs 7649/10万男性,度他雄胺单药149 vs 336/10万男性。
  • BPH总手术率92 vs 133/10万男性;TURP使用率118 vs 89/10万男性(2009年后)。

临床怎么用

  • 临床应关注BPH药物治疗处方增长带来的费用负担,并评估药物对疾病进展的实际影响。
  • TURP使用减少而激光与微创手术增加,需根据患者情况选择替代术式。

局限性

  • 研究为回顾性人群数据分析,未探讨特定治疗选择的驱动因素。
  • 药物治疗对BPH进展的影响需在临床试验外的临床实践中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine national trends in the medical and surgical treatment of benign prostatic hyperplasia (BPH) using Australian Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Scheme (PBS) population data from 2000 to 2018. PATIENTS AND METHODS: Annual data was extracted from the MBS, PBS and Australian Institute of Health and Welfare databases for the years 2000-2018. Population-adjusted rates of BPH procedures and medical therapies were calculated and compared in relation to age. Cost analysis was performed to estimate financial burden due to BPH. RESULTS: Overall national hospital admissions due to BPH declined between 2000 and 2018, despite an increased proportion of admissions due to private procedures (42% vs 77%). Longitudinal trends in the medical management of BPH showed an increased prescription rate of dutasteride/tamsulosin combined therapy (111 vs 7649 per 100 000 men) and dutasteride monotherapy (149 vs 336 per 100 000 men) since their introduction to the PBS in 2011. Trends in BPH surgery showed an overall progressive increase in rate of total procedures between 2000 and 2018 (92 vs 133 per 100 000 men). Transurethral resection of the prostate (TURP) remained the most commonly performed surgical procedure, despite reduced utilisation since 2009 (118 vs 89 per 100 000 men), offset by a higher uptake of photoselective vaporisation of prostate, holmium:YAG laser enucleation of prostate, and later likely due to minimally invasive surgical therapies including prostatic urethral lift and ablative technologies (including Rezūm™). Financial burden due to BPH surgery has remained steady since 2009, whilst the burden due to medical therapy has risen sharply. CONCLUSION: Despite reduced national BPH-related hospitalisations, overall treatment for BPH has increased due to medical therapy and surgical alternatives to TURP. Further exploration into motivators for particular therapies and effect of medical therapy on BPH progression in clinical practice outside of clinical trials is warranted.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Morton A, Williams M, Perera M, et al. Management of benign prostatic hyperplasia in the 21st century: temporal trends in Australian population-based data. BJU Int. 2020. PMID: 32558340. doi:10.1111/bju.15098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。